

March 29, 2023

Company Name: HEALIOS K.K.  
Representative: Hardy TS Kagimoto, Chairman & CEO  
(TSE Growth Code: 4593)  
Contact: Richard Kincaid, Executive Officer CFO  
(TEL: 03-4590-8009)

## **Determination of medical expert for initiation of clinical trials for iPS cell-derived RPE cells**

HEALIOS K.K. (“Healios”) is developing a treatment using iPS cell-derived retinal pigment epithelial (RPE) cells (development code: HLCR011) with our co-development partner in Japan, Sumitomo Pharma Co., Ltd. (hereinafter “Sumitomo Pharma”). Healios announces that Professor Taiji Sakamoto of Kagoshima University, Department of Ophthalmology has been selected as the medical expert for the trial prior to its launch. With the continued cooperation of Dr. Sakamoto, Sumitomo Pharma will take the lead in preparing for the early submission of the clinical trial plan.

Commenting on the decision, Tadahisa Kagimoto, MD, Chairman and CEO of Healios, said, “Regenerative medicine is an area of industry in which the Japanese government has been investing intensively, and we are working towards the establishment of treatment methods and industrialization. Since the foundation of Healios, we have been entrusted with this responsibility and have been co-developing RPE cells with Sumitomo Pharma. Above all, for the sake of patients who are waiting for new therapies and stakeholders who have been looking forward to the practical application of iPS cells, we will strive for their commercialization as soon as possible.”

This matter has no impact on our business performance for the fiscal year ending December 2023 at this time. Healios shall promptly announce all future matters that require disclosure, including any potential impact on expenses associated with launching this clinical trial.